Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Recruiting · NCT05476770 · Registry updated 2024-12-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | B-cell neoplasm, CD4+/CD56+ hematodermic neoplasm, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, Neoplasms by Site, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Skin and Connective Tissue Diseases, T-cell non-Hodgkin lymphoma, acute biphenotypic leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, acute undifferentiated leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mixed phenotype acute leukemia, myelodysplastic syndrome, neoplasm, skin disorder, skin neoplasm | Recruiting | Phase 1 | 2024-12-06 | NCT05476770 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Therapeutic Advances in Childhood Leukemia Consortium | 5 |
31 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.